TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA therapeutics for high-risk and advanced cancers, announced the retirement of Chief Financial Officer Tom Fitzgerald, effective immediately. Fitzgerald, who also served as a director, will continue to provide transition services to ensure a smooth handover. The company has appointed John Tattory as interim CFO, effective immediately.
Tattory brings over 25 years of financial and operational management experience across the pharmaceutical, medical device, and biotechnology sectors. His career includes roles at Ernst & Young LLP, Bristol-Myers Squibb, Tyco International, Cerapedics, and Windtree Therapeutics. Currently, he serves as a managing director at Stout Risius Ross, where he provides consulting CFO services primarily to privately held life science companies. His deep expertise in financial leadership within the life sciences industry is expected to be instrumental as TransCode continues to advance its clinical programs.
The leadership change comes at a critical time for TransCode, which is focused on developing innovative treatments for metastatic cancers. The company’s lead therapeutic candidate, TTX-MC138, targets metastatic tumors that overexpress microRNA-10b, a well-documented biomarker of metastasis. In addition, TransCode has a portfolio of other first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells. The appointment of an interim CFO with Tattory’s background ensures financial continuity and strategic oversight as the company navigates the complex landscape of clinical development and potential commercialization.
Investors and industry observers will be watching closely to see how this transition impacts TransCode’s financial strategy and operational execution. The company’s ability to maintain momentum in its clinical trials and secure necessary funding is paramount. Tattory’s experience with both large pharmaceutical companies and smaller biotechnology firms may provide valuable insights as TransCode seeks to optimize its capital structure and drive shareholder value.
For more details on this announcement, visit the full press release at https://nnw.fm/8G3ik. The latest news and updates relating to RNAZ are available in the company’s newsroom at https://nnw.fm/RNAZ.
TransCode Therapeutics remains committed to its mission of developing breakthrough therapies for high-risk and advanced cancers. With a strong pipeline and a seasoned interim CFO, the company is well-positioned to continue its pioneering work in immuno-oncology and RNA therapeutics.
